| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Meenhard Herlyn | Q16732421 |
| Dwight A. Towler | Q40296435 | ||
| P2093 | author name string | Leland W K Chung | |
| Michael L Cher | |||
| Shahin Rafii | |||
| Evan Keller | |||
| Eun Ah Cho | |||
| Henry J Donahue | |||
| David Rowley | |||
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand | Q24644662 | ||
| Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment | Q30304016 | ||
| Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis | Q33358404 | ||
| Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model | Q34266934 | ||
| Reactive stroma in prostate cancer progression | Q34429976 | ||
| Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue | Q35083825 | ||
| Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease | Q35124704 | ||
| Angiogenesis and marrow stromal cell fates: roles in bone strength | Q35541093 | ||
| Prostate cancer bone metastases promote both osteolytic and osteoblastic activity | Q35678564 | ||
| Tie2 activation contributes to hemangiogenic regeneration after myelosuppression | Q35847986 | ||
| Mesenchymal stem cells and the artery wall. | Q35905888 | ||
| Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment | Q37426670 | ||
| CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. | Q38321879 | ||
| Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. | Q38362968 | ||
| Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 | ||
| Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis | Q40365781 | ||
| Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway | Q40444119 | ||
| Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells | Q40536020 | ||
| Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication | Q40816032 | ||
| Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals | Q42717983 | ||
| Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. | Q42814631 | ||
| Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis | Q43843519 | ||
| Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. | Q44024861 | ||
| Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms | Q46585287 | ||
| Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model | Q78469525 | ||
| Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone | Q79317200 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | workshop | Q27556165 |
| P304 | page(s) | 1405-1412 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section | |
| P478 | volume | 168 |
| Q46760547 | 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases |
| Q33703810 | COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems |
| Q54500167 | Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw. |
| Q34417941 | Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit |
| Q38584982 | New cancer therapies and jaw necrosis |
| Q34249263 | Novel therapies for metastatic castrate-resistant prostate cancer |
| Q36962989 | Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients |
| Q30683446 | Rapid ex vivo imaging of PAIII prostate to bone tumor with SWIFT-MRI |
| Q35580309 | SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis |
| Q37601043 | Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). |
Search more.